Discovery of a highly selective PLD2 inhibitor (ML395): A new probe with improved physiochemical properties and broad-spectrum antiviral activity against influenza strains

ChemMedChem

Volumn 9, Issue 12, 2014, Pages 2633-2637

  O'Reilly, Matthew C ^a   Oguin, Thomas H ^b   Scott, Sarah A ^a   Thomas, Paul G ^b   Locuson, Charles W ^a   Morrison, Ryan D ^a   Daniels, J Scott ^a   Brown, H Alex ^a   Lindsley, Craig W ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Antivirals; Inhibitors; Lipids; Phospholipase D; PLD2

Indexed keywords

ANTIVIRUS AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; HALOPEMIDE; ML 395; PHOSPHOLIPASE D1; PHOSPHOLIPASE D2; PHOSPHOLIPASE D2 INHIBITOR; UNCLASSIFIED DRUG; IMIDAZOLIDINE DERIVATIVE; PHOSPHOLIPASE D; PROTEIN BINDING; SPIRO COMPOUND; VU0468809;

ALLOSTERISM; ANTIVIRAL ACTIVITY; ARTICLE; CENTRAL NERVOUS SYSTEM; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; IC50; IN VITRO STUDY; INFLUENZA VIRUS; MALE; NONHUMAN; PHYSICAL CHEMISTRY; RAT; STRUCTURE ACTIVITY RELATION; VIRUS STRAIN; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; CHEMISTRY; DOG; DRUG EFFECTS; HALF LIFE TIME; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); INFLUENZA A VIRUS (H5N1); INFLUENZA A VIRUS (H7N9); MDCK CELL LINE; METABOLISM; SPRAGUE DAWLEY RAT; TUMOR CELL LINE;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; DOGS; HALF-LIFE; HUMANS; IMIDAZOLIDINES; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA A VIRUS, H7N9 SUBTYPE; MADIN DARBY CANINE KIDNEY CELLS; PHOSPHOLIPASE D; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; SPIRO COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84915746216     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.201402333     Document Type: Article

References (14)

1. P. E. Selvy, R. Lavieri, C. W. Lindsley, H. A. Brown, Chem. Rev. 2011, 111, 6064-6119.
2. S. A. Scott, P. E. Selvy, J. R. Buck, H. P. Cho, T. L. Criswell, A. L. Thomas, M. D. Armstrong, C. L. Arteaga, C. W. Lindsley, H. A. Brown, Nat. Chem. Biol. 2009, 5, 108-117.
3. H. A. Brown, L. G. Henage, A. M. Preininger, Y. Xiang, J. H. Exton, Methods Enzymol. 2007, 434, 49-87.
4. S. A. Scott, T. P. Matthews, P. T. Ivanova, C. W. Lindsley, H. A. Brown, Biochim. Biophys. Acta 2014, 1841, 1060-1084.
5. L. Monovich, B. Mugrage, E. Quadros, K. Toscano, R. Tommasi, S. LaVoie, E. Liu, Z. M. Du, D. LaSala, W. Boyar, P. Steed, Bioorg. Med. Chem. Lett. 2007, 17, 2310-2311.
6. H. De Cuyper, H. M. van Praag, D. Verstraeten, Neuropsychobiology 1984, 12, 211-223.
7. J. A. Lewis, S. A. Scott, R. Lavieri, J. R. Buck, P. E. Selvy, S. L. Stoops, M. D. Armstrong, H. A. Brown, C. W. Lindsley, Bioorg. Med. Chem. Lett. 2009, 19, 1916-1919.
8. R. Lavieri, J. A. Lewis, S. A. Scott, P. E. Selvy, J. Buck, M. D. Armstrong, H. A. Brown, C. W. Lindsley, Bioorg. Med. Chem. Lett. 2009, 19, 2240-2244.
9. R. Lavieri, S. A. Scott, P. E. Selvy, H. A. Brown, C. W. Lindsley, J. Med. Chem. 2010, 53, 6706-6719.
10. M. C. O'Reilly, S. A. Scott, K. A. Brown, T. H. Oguin III, P. G. Thomas, J. S. Daniels, R. Morrison, H. A. Brown, C. W. Lindsley, J. Med. Chem. 2013, 56, 2695-2699.
11. For experimental details of the molecular pharmacology, DMPK, antiviral assays, chemical synthesis and characterization, see the Supporting Information.
12. For informaiton on the Eurofins Lead Profiling Screen, see: http://www.eurofins.com.
13. T. Oguin III, S. Sharma, A. D. Stuart, C. K. Jones, J. S. Daniels, C. W. Lindsley, P. G. Thomas, H. A. Brown, J. Biol. Chem. 2014, DOI: 10.1074/jbc.M114.558817.
14. Y. Hu, S. Lu, W. Wang, P. Hao, J. Li, H-L. Yen, B. Shi, T. Li, W. Guan, L. Zu, Y. Liu, X. Zhang, D. Tian, Z. Zhu, J. He, K. Huang, H. Chen, L. Zheng, X. Li, J. Ping, B. Kang, X. Xi, L. Zha, Z. Zhang, M. Peiris, Z. Yuan, Lancet 2013, 381, 2273-2279.